GlassScriptPhysician profile
Bill M Law
NPI 1720084825
$2,795.73
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $160 · 2021: $506 · 2022: $1,247 · 2023: $73.61 · 2024: $29.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $381.90 | 2019-2022 | |
| Novo Nordisk INC | $352.00 | 2019-2022 | |
| Lilly USA, LLC | $320.38 | 2019-2022 | |
| Mannkind Corporation | $231.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.31 | 2022-2023 | |
| Abbott Laboratories | $143.59 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $120.13 | 2019-2022 | |
| Insulet Corporation | $103.90 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $98.46 | 2022 | |
| Tandem Diabetes Care, INC. | $93.56 | 2020-2022 | |
| Corcept Therapeutics | $88.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.15 | 2021-2022 | |
| Amarin Pharma, INC. | $71.09 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.47 | 2021-2022 | |
| Nevro Corp. | $67.29 | 2021-2023 | Senza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $57.25 | 2021-2022 | |
| Radius Health, INC. | $51.98 | 2019-2022 | |
| Senseonics, Incorporated | $45.00 | 2019 | |
| Pfizer INC. | $44.30 | 2021-2022 | |
| Dexcom, INC. | $35.73 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $31.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.20 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $29.18 | 2024 | Crysvita |
| Abbvie INC. | $26.11 | 2019-2022 | |
| Valeritas, INC. | $23.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2021 | |
| Ibsa Pharma INC. | $14.82 | 2022 | |
| Alexion Pharmaceuticals, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.